Glenmede Trust CO Na Fate Therapeutics Inc Transaction History

Glenmede Trust CO Na

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 16, 2022	BUY	$21.04 - $36.06 $194,514 - $333,374	9,245 New	9,245 $207,000
Q4 2020 Feb 16, 2021	SELL	$38.09 - $100.95 $28,262 - $74,904	-742 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$30.41 - $40.5 $21,651 - $28,836	712 Added 2373.33%	742 $29,000
Q2 2020 Aug 14, 2020	BUY	$20.21 - $35.23 $606 - $1,056	30 New	30 $1,000
Q1 2019 May 14, 2019	SELL	$13.15 - $18.71 $14,070 - $20,019	-1,070 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$11.48 - $16.98 $12,283 - $18,168	1,070 New	1,070 $13,000
Q3 2018 Nov 15, 2018	SELL	$8.75 - $16.29 $29,925 - $55,711	-3,420 Closed	0 $0
Q2 2018 Aug 15, 2018	BUY	$9.16 - $13.48 $31,327 - $46,101	3,420 New	3,420 $39,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $260M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

Stay updated on Glenmede Trust CO Na with notifications on news.